Tanezumab

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

Positive Phase 3 Results for Novel OA Pain Treatment Tanezumab

By

The 16-week, double-blind, placebo-controlled, multicenter, parallel-group study included 698 patients who were randomized to 3 treatment groups: 2 doses of tanezumab 2.5mg; 1 dose of tanezumab 2.5mg followed by tanezumab 5mg, or 2 doses of placebo; each injection was administered once every 8 weeks.

Subcutaneous vs Intravenous Tanezumab for Knee, Hip Osteoarthritis

Subcutaneous vs Intravenous Tanezumab for Knee, Hip Osteoarthritis

By

Intravenous and subcutaneous administration of tanezumab may provide similar analgesia and tolerability in patients with hip or knee osteoarthritis.

First-in-Class Chronic Pain Drug Candidate Fast Tracked

First-in-Class Chronic Pain Drug Candidate Fast Tracked

By

Tanezumab is a NGF inhibitor and is a first-in-class agent to receive Fast Track approval.

Sign Up for Free e-Newsletters